Seeking Alpha·Sep 14, 2026
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sana Biotechnology is a pre-revenue clinical-stage biotech executing a deliberate cash-preservation pivot, cutting quarterly net losses from $107.5M in 2024Q1 to $63.6M in 2026Q2 while prioritizing key clinical assets. However, the balance sheet is critically ...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.22-49.8% vs -$0.15 | — vs — |
Q3 2026 Aug 10, 2026 | -$0.13+11.5% vs -$0.15 | — vs — |
Q2 2026 May 11, 2026 | -$0.14+6.7% vs -$0.15 | — vs — |
Q2 2026 Mar 3, 2026 | -$0.16-23.1% vs -$0.13 | — vs — |
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Benchmark SANA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Sana Biotechnology, Inc. (SANA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.89 | $804.26M | -3.01 | — | — | -118.7% | — | |
| $2.32 | $270.42M | -2.02 | -51.24% | -1941.09% | -65.08% | — | |
| $55.43 | $5.35B | -8.57 | -89.97% | -3368.72% | -24.39% | — | |
| $24.50 | $2.52B | -30.25 | 120.01% | -54.75% | -7.7% | — | |
| $2.62 | $402.07M | -1.46 | 25.39% | -157.32% | -196.63% | — | |
| $12.26 | $1.38B | -3.22 | 16.92% | -672.16% | -57.79% | — |
Sana Biotechnology, Inc. (SANA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Sana Biotechnology, Inc. (SANA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Jun 5, 2026·SEC
May 15, 2026·SEC
Get notified when SANA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sana Biotechnology, Inc. (SANA) stock FAQ — growth, dividends, profitability & financials explained
Sana Biotechnology, Inc. (SANA) reported a net loss of $211.8M for fiscal year 2025.
Sana Biotechnology, Inc. (SANA) has a return on equity (ROE) of -118.7%. Negative ROE indicates the company is unprofitable.
Sana Biotechnology, Inc. (SANA) had negative free cash flow of $135.1M in fiscal year 2025, likely due to heavy capital investments.
